羚锐制药2024年归母净利润增长27.2%至7.23亿元

财中社2025-04-25

4月25日，羚锐制药(600285)公布2024年年报，公司营业收入为35.0亿元，同比上升5.7%；归母净利润为7.23亿元，同比上升27.2%；扣非归母净利润为6.42亿元，同比上升20.2%；经营现金流净额为8.76亿元，同比增长7.7%；EPS(全面摊薄)为1.2741元。其中第四季度，公司营业收入为7.42亿元，同比下降7.8%；归母净利润为1.49亿元，同比上升45.9%；扣非归母...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2530041299?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-25 17:44","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530041299","market":"sh","top_or_hot":-1,"title":"羚锐制药2024年归母净利润增长27.2%至7.23亿元","media":"财中社","content":"<div>\n<p>4月25日，羚锐制药(600285)公布2024年年报，公司营业收入为35.0亿元，同比上升5.7%；归母净利润为7.23亿元，同比上升27.2%；扣非归母净利润为6.42亿元，同比上升20.2%；经营现金流净额为8.76亿元，同比增长7.7%；EPS(全面摊薄)为1.2741元。其中第四季度，公司营业收入为7.42亿元，同比下降7.8%；归母净利润为1.49亿元，同比上升45.9%；扣非归母...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425175928a6c7dcfd&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>羚锐制药2024年归母净利润增长27.2%至7.23亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n羚锐制药2024年归母净利润增长27.2%至7.23亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-25 17:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425175928a6c7dcfd&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月25日，羚锐制药(600285)公布2024年年报，公司营业收入为35.0亿元，同比上升5.7%；归母净利润为7.23亿元，同比上升27.2%；扣非归母净利润为6.42亿元，同比上升20.2%；经营现金流净额为8.76亿元，同比增长7.7%；EPS(全面摊薄)为1.2741元。其中第四季度，公司营业收入为7.42亿元，同比下降7.8%；归母净利润为1.49亿元，同比上升45.9%；扣非归母...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425175928a6c7dcfd&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600285","symbol_name":"羚锐制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425175928a6c7dcfd&s=b","article_id":"2530041299","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425175928a6c7dcfd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530041299","pubTimestamp":1745574274,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"4月25日，羚锐制药公布2024年年报，公司营业收入为35.0亿元，同比上升5.7%；归母净利润为7.23亿元，同比上升27.2%；扣非归母净利润为6.42亿元，同比上升20.2%；经营现金流净额为8.76亿元，同比增长7.7%；EPS为1.2741元。截至四季度末，公司总资产50.17亿元，较上年度末增长5.1%；归母净资产为30.73亿元，较上年度末增长10.1%。公司在2024年度报告中强调了其经营情况的显著改善和创新发展。文章来源：财中社羚锐制药2024年归母净利润增长27.2%至7.23亿元","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"600285":"羚锐制药"},"translate_title":"Lingrui Pharmaceutical's net profit attributable to the parent company will increase by 27.2% to 723 million yuan in 2024","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600285":1},"content_text":"4月25日，羚锐制药(600285)公布2024年年报，公司营业收入为35.0亿元，同比上升5.7%；归母净利润为7.23亿元，同比上升27.2%；扣非归母净利润为6.42亿元，同比上升20.2%；经营现金流净额为8.76亿元，同比增长7.7%；EPS(全面摊薄)为1.2741元。其中第四季度，公司营业收入为7.42亿元，同比下降7.8%；归母净利润为1.49亿元，同比上升45.9%；扣非归母净利润为1.01亿元，同比上升9.0%；EPS为0.2622元。截至四季度末，公司总资产50.17亿元，较上年度末增长5.1%；归母净资产为30.73亿元，较上年度末增长10.1%。公司在2024年度报告中强调了其经营情况的显著改善和创新发展。管理层表示，公司聚焦医药主业，强化品牌建设与市场开拓，积极推进数字化、智能化升级，提升生产管理水平。特别是在信阳分公司，新的丸剂和口服液体制剂生产线建设完成，为未来产品扩展奠定了基础。同时，智能化物流仓储项目的启动将助力公司在医药产业全链条的发展。在研发和并购方面，报告指出公司加强了外用制剂的布局，获得了多项新药注册证书，并与中原学者合作的中医药研究课题已完成验收，提升了研发成果的产业化能力。此外，公司完成了对银谷制药的控股收购，这一举措不仅丰富了产品线，还增强了市场竞争力，特别是在技术门槛较高的鼻喷剂和吸入剂领域。文章来源：财中社原标题：羚锐制药2024年归母净利润增长27.2%至7.23亿元","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2530041299","isCrawlerRequest":true}